Table 1 Baseline characteristics of the patients whose samples were analyzed by RNAseq (n = 55)
Number of samples (%) | |
|---|---|
Anastrozole therapy (Arm A) | 26 (47.3) |
Fulvestrant therapy (Arm B) | 29 (52.7) |
Age, mean (range), years | 72.1 (51–88) |
Age | |
≤ 70 years | 21 (38.2) |
> 70 years | 32 (61.8) |
ECOG PS | |
0 | 45 (81.8) |
1 | 10 (18.2) |
Hormone replacement therapy | |
Yes | 18 (32.7) |
No | 37 (67.2) |
Tumor staging | |
T2 | 45 (81.8) |
T3 | 7 (12.7) |
T4 | 3 (5.5) |
Node staging | |
N0 | 35 (63.6) |
N1 | 17 (30.9) |
N2 | 2 (3.6) |
N3 | 1 (1.7) |
Elston-Ellis grade | |
I | 11 (20.0) |
II | 38 (69.1) |
III | 6 (10.9) |
Histological type | |
Ductal | 37 (67.3) |
Lobular | 15 (27.3) |
Other | 3 (5.4) |
Allred score: ER | |
5 | 1 (1.8) |
6 | 3 (5.5) |
7 | 7 (12.7) |
8 | 44 (80.0) |
Allred score: PR | |
0–5 | 21 (38.2) |
6 | 11 (20.0) |
7 | 11 (20.0) |
8 | 12 (21.8) |
Ki-67 | |
≥ 20% | 14 (25.5) |
< 20% | 39 (70.9) |
ND | 2 (3.6) |